← Back to Clinical Trials
Recruiting NCT06564805

NCT06564805 Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06564805
Status Recruiting
Phase
Sponsor Universidad Autonoma de Nuevo Leon
Condition Alopecia Areata
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2024-08-20
Primary Completion 2025-07-30

Eligibility & Interventions

Sex All sexes
Min Age 6 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Candida Albicans Antigen Injection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2024-08-20 with a primary completion date of 2025-07-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of alopecia areata * SALT score of less than 50% extension * Has not received any topical or systemic treatment in the last month * Signed informed consent Exclusion Criteria: * Any skin condition on the scalp (infectious, inflammatory or neoplastic) that could modify the clinical of trichoscopic features * Pregnancy or breast-feeding * Patients in medications that could cause hair loss as side-effects

Contact & Investigator

Central Contact

Erika Alba-Rojas, MD

✉ eri9ar@yahoo.com

📞 +528183891111

Principal Investigator

Fania Muñoz Garza, PhD

PRINCIPAL INVESTIGATOR

Hospital Universitario "Dr. José E. González"

Frequently Asked Questions

Who can join the NCT06564805 clinical trial?

This trial is open to participants of all sexes, aged 6 Years or older, studying Alopecia Areata. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06564805 currently recruiting?

Yes, NCT06564805 is actively recruiting participants. Contact the research team at eri9ar@yahoo.com for enrollment information.

Where is the NCT06564805 trial being conducted?

This trial is being conducted at Monterrey, Mexico.

Who is sponsoring the NCT06564805 clinical trial?

NCT06564805 is sponsored by Universidad Autonoma de Nuevo Leon. The principal investigator is Fania Muñoz Garza, PhD at Hospital Universitario "Dr. José E. González". The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology